Biorestorative Therapies (BRTX) Stock Price, News & Analysis

Company Overview

Biorestorative Therapies, Inc. (NASDAQ: BRTX) is a clinical-stage biotechnology company focused on developing regenerative medical products designed to address unmet needs in tissue repair and functional restoration. Leveraging proprietary platforms of allogeneic microtissue and acellular constructs, the company aims to accelerate healing, reduce fibrosis and enhance organ recovery across a range of therapeutic areas. Its pipeline includes candidates targeting musculoskeletal injuries, cardiovascular complications and ophthalmologic disorders, each grounded in the company’s expertise in extracellular matrix biology and immunomodulation.

Headquartered in San Francisco, California, Biorestorative operates research and development facilities equipped for both preclinical and clinical-stage work. The company collaborates with leading academic institutions and contract manufacturing organizations to advance its product candidates, while maintaining a robust patent portfolio that safeguards its proprietary technologies. Biorestorative’s strategic partnerships support scale-up capabilities and strengthen its position in the competitive regenerative medicine landscape.

Founded in 2020, Biorestorative has achieved several significant milestones, including successful completion of key preclinical studies that demonstrate safety and efficacy of its flagship microtissue therapy, the initiation of human proof-of-concept trials, and the establishment of manufacturing processes aligned with regulatory requirements. These accomplishments reflect the team’s deep experience in biotechnology and regenerative medicine, with leadership drawn from industry veterans who have held senior roles at prominent life sciences organizations.

Under the direction of its executive team, Biorestorative Therapies continues to expand its pipeline through rigorous translational research and constructive engagement with regulatory agencies. The company’s mission is to transform standards of care for patients with chronic and degenerative conditions by delivering innovative therapeutics that restore function and improve quality of life. With a commitment to scientific excellence and patient-focused development, Biorestorative positions itself as a promising player in the evolving field of regenerative healthcare.

Key Stats

• Today's Range: $1.56 to $1.58
• 50-Day Range: $1.52 to $2.00
• 52-Week Range: $1.21 to $2.55
• Volume: 4,432 shs
• Average Volume: 144,568 shs
• Market Capitalization: $11.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Biorestorative Therapies Stock Analysis - MarketRank™

Biorestorative Therapies scored higher than 72% of companies evaluated by MarketBeat, and ranked 256th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Biorestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Biorestorative Therapies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biorestorative Therapies are expected to grow in the coming year, from ($1.43) to ($0.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biorestorative Therapies is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biorestorative Therapies is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biorestorative Therapies has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.75% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 22.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biorestorative Therapies does not currently pay a dividend.

Dividend Growth

Biorestorative Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.75% of the float of Biorestorative Therapies has been sold short.

Short Interest Ratio / Days to Cover

Biorestorative Therapies has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biorestorative Therapies has recently decreased by 22.15%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.94

News Sentiment

Biorestorative Therapies has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biorestorative Therapies this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 2 people have added Biorestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biorestorative Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.50% of the stock of Biorestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.38% of the stock of Biorestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BRTX Stock Analysis - Frequently Asked Questions

How have BRTX shares performed this year?

Biorestorative Therapies' stock was trading at $1.43 at the start of the year. Since then, BRTX stock has increased by 9.4% and is now trading at $1.5650.

How were Biorestorative Therapies' earnings last quarter?

Biorestorative Therapies, Inc. (NASDAQ:BRTX) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.24. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.38 million. Biorestorative Therapies had a negative trailing twelve-month return on equity of 129.47% and a negative net margin of 3,093.61%.
Read the conference call transcript.

Is Biorestorative Therapies doing a stock buyback?

Biorestorative Therapies' Board of Directors approved a stock buyback program on Tuesday, June 17th 2025, which permits the company to buy back $2,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 15.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.

How do I buy shares of Biorestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biorestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biorestorative Therapies investors own include NVIDIA (NVDA), Micron Technology (MU), PayPal (PYPL), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Broadcom (AVGO) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:BRTX
• CIK: 1505497
• Web: www.biorestorative.com
• Phone: 631-760-8100
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biorestorative Therapies: $18.00
• High Price Target: $18.00
• Low Price Target: $18.00
• Potential Upside/Downside: +1,068.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.98 million
• Net Margins: -3,093.61%
• Pretax Margin: -3,093.61%
• Return on Equity: -129.47%
• Return on Assets: -86.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.24
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: $400 thousand
• Price / Sales: 28.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 7,500,000
• Free Float: 5,591,000
• Market Cap: $11.55 million
• Optionable: Not Optionable
• Beta: 75.28